Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.

The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.

The company was incorporated in 2016 and is headquartered in Austin, Texas.